Proud For Profits
  • Investing
  • Stock
  • Latest News
  • Economy
  • Investing
  • Stock
  • Latest News
  • Economy
No Result
View All Result
Proud For Profits
No Result
View All Result
Home Stock

Birkenstock’s quarterly revenue beats on resilient demand

by
December 18, 2024
in Stock
0
Birkenstock’s quarterly revenue beats on resilient demand

(Reuters) -Birkenstock beat market expectations for fourth-quarter revenue on Wednesday, helped by robust full-price sales of the German footwear maker’s pricey sandals in the United States and Asia.

With fresh styles becoming a priority for consumers, particularly in its largest market in the Americas, Birkenstock (NYSE:BIRK)’s sandals and close-toed clogs alike have drawn new customers to its stores.

This has also allowed the company to raise prices for clogs, which increased 8% in the fiscal year ended Sept. 30.

Birkenstock’s shares were marginally lower in premarket trading after the company forecast fiscal 2025 revenue growth below market expectations.

Shoppers have approached non-essential purchases with caution despite cooling inflation, carefully comparing prices, a trend also at play during the on-going holiday season.

This has resulted in some softness in expectations from retailers in the U.S. for 2025.

Birkenstock, which debuted on the New York Stock Exchange in October 2023, invested in expanding its store presence in markets such as Japan and China, as well as increasing its manufacturing capacity this year to meet global demand.

The company reported fourth-quarter revenue of 455.8 million euros ($478.27 million), compared with the average analyst estimate of 439.2 million euros, according to data compiled by LSEG.

Birkenstock expects fiscal 2025 revenue to grow between 15% and 17%, compared with estimates of 17.5% growth.

($1 = 0.9530 euros)

This post appeared first on investing.com
Previous Post

Renault open in principle to Nissan pursuing merger talks with Honda, sources say

Next Post

EU to review studies linking Novo Nordisk’s Ozempic to rare eye condition

Next Post
EU to review studies linking Novo Nordisk’s Ozempic to rare eye condition

EU to review studies linking Novo Nordisk’s Ozempic to rare eye condition

Enter Your Information Below To Receive Trading Ideas and Latest News

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    Popular News

    As Biden wraps up half-century political career, his failure to turn page on Trump weighs on president

    As Biden wraps up half-century political career, his failure to turn page on Trump weighs on president

    January 18, 2025
    Highlights from President-elect Donald Trump’s 1st Inauguration Day; what to expect from Monday

    Highlights from President-elect Donald Trump’s 1st Inauguration Day; what to expect from Monday

    January 18, 2025
    Long Bonds Continue to Break Down

    Long Bonds Continue to Break Down

    January 18, 2025
    Track all markets on TradingView

    About Proud For Profits

    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Main Categories

    • Investing
    • Stock
    • Latest News
    • Economy

    Latest News

    • As Biden wraps up half-century political career, his failure to turn page on Trump weighs on president
    • Highlights from President-elect Donald Trump’s 1st Inauguration Day; what to expect from Monday
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 proudforprofits.com | All Rights Reserved

    No Result
    View All Result
    • Investing
    • Stock
    • Latest News
    • Economy

    Copyright © 2025 proudforprofits.com | All Rights Reserved